CANbridge Pharmaceuticals Inc.

1228

KYG1821D1097

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 09:57:53 2024-04-29 pm EDT			5-day change	1st Jan Change
0.455 ^HKD	+9.64%		-4.21%	-54.04%

Apr. 23	Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials	MT
Apr. 12	CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024	CI

CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024

April 12, 2024 at 06:10 am EDT

The board of directors of CANbridge Pharmaceuticals Inc. announced that the principal place of business of the Company in Hong Kong will be changed to Room B01, 20/F, CITIC Tower, 1 Tim Mei Avenue, Admiralty, Hong Kong with effect from April 15, 2024. The website of the Company remain unchanged.

Latest news about CANbridge Pharmaceuticals Inc.

Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials	Apr. 22	MT
CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024	Apr. 12	CI
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares	Feb. 07	MT
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee	Nov. 23	CI
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress	23-10-25	CI
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	23-10-16	CI
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China	23-10-16	CI
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	23-10-08	CI
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows	23-08-31	MT
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Transcript : CANbridge Pharmaceuticals Inc. - Special Call	23-06-27
CANbridge Pharmaceuticals Releases Phase 1B Data for Red Blood Cell Disorder Treatment	23-06-25	MT
CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart in Paroxysmal Nocturnal Hemoglobinuria	23-06-25	CI
Transcript : CANbridge Pharmaceuticals Inc. - Special Call	23-06-06
CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	23-06-02	CI
CANbridge Pharmaceuticals Gets China Marketing Approval for Liver Disease Medication	23-06-01	MT
CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) EMBARK Phase 2 Study in Biliary Atresia	23-05-30	CI
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
CANbridge Pharmaceuticals, Inc. Completes Enrollment in Phase 2 Trial for the Treatment of Glioblastoma Multiforme in China	23-03-27	CI
CANbridge Pharmaceuticals Inc. Announces Long-Term Data from CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67%	23-03-16	CI
CANbridge Pharmaceuticals Remains Unaffected by Silicon Valley Bank Closure	23-03-13	MT
Over a dozen Chinese-based firms say they have minimal exposure to SVB	23-03-12	RE
Six Hong Kong-listed firms say their deposits at SVB are immaterial	23-03-12	RE
CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China	23-01-18	CI

Chart CANbridge Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

CANbridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The Company is also engaged in the development of gene therapy.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CANbridge Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.415 HKD

Average target price

7 HKD

Spread / Average Target

+1,586.75%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CANBRIDGE PHARMACEUTICALS INC.	-54.04%	22.53M
MERCK KGAA	+4.06%	69.85B
KYOWA KIRIN CO. LTD.	+11.73%	8.98B
SK BIOPHARMACEUTICALS CO., LTD.	-14.44%	4.89B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+41.60%	4.44B
YUHAN CORPORATION	+5.96%	3.95B
INDIVIOR PLC	+23.46%	2.49B
BETTA PHARMACEUTICALS CO., LTD.	-19.32%	2.4B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-27.04%	2.28B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.97%	1.96B

Specialty & Advanced Pharmaceuticals